Novartis Pharmaceuticals $NVS
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS180
PHASE 3 / 2-388
RECRUITING79
READOUTS ≤12 MONTHS51
READOUT SLIPPED >6 MO42%
Delay Index: of 140 active trials registered more than a year ago, 59 have moved their primary completion (readout) date by more than 6 months since first registration (median +3.1 months). See all sponsors →
Open Novartis Pharmaceuticals on the live radar map → 📅 $NVS readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Interferon beta-1a NCT01892722 |
P3 | Active, not recruiting | Multiple Sclerosis | 240 | 2017-07-14 (+7 mo) |
| inclisiran sodium NCT04765657 |
P3 | Active, not recruiting | Hypercholesterolemia | 345 | 2022-06-09 (-1 mo) |
| STAND NCT03814746 |
P3 | Active, not recruiting | Sickle Cell Disease (SCD) | 253 | 2022-08-31 (+3 mo) |
| MANIFEST-2 NCT04603495 |
P3 | Active, not recruiting | Myelofibrosis; Primary Myelofibrosis | 430 | 2023-08-23 (+12 mo) |
| Imatinib NCT04971226 |
P3 | Active, not recruiting | Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | 405 | 2023-11-28 (-10 mo) |
| EPIK-P2 NCT04589650 |
P2 | Active, not recruiting | PIK3CA-related Overgrowth Spectrum (PROS) | 236 | 2024-03-20 (+14 mo) |
| AFFINITY NCT04573920 |
P2 | Active, not recruiting | IgA Nephropathy; Focal Segmental Glomerulosclerosis | 103 | 2024-07-02 (+19 mo) |
| LOU064 (blinded) NCT05513001 |
P3 | Active, not recruiting | Chronic Spontaneous Urticaria | 696 | 2024-08-26 (-30 mo) |
| KontRASt-06 NCT05445843 |
P2 | Active, not recruiting | Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation | 95 | 2024-11-04 (-24 mo) |
| [177Lu]Lu-PSMA-617 NCT05658003 |
P2 | Active, not recruiting | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 63 | 2024-12-02 (-23 mo) |
| PSMAddition NCT04720157 |
P3 | Active, not recruiting | Prostatic Neoplasms | 1144 | 2025-01-13 (-29 mo) |
| Dabrafenib NCT04940052 |
P3 | Active, not recruiting | Differentiated Thyroid Cancer (DTC) | 153 | 2025-01-22 (+11 mo) |
| Ianalumab NCT05885555 |
P2 | Active, not recruiting | Primary Immune Thrombocytopenia (ITP) | 41 | 2025-02-05 (+4 mo) |
| Eltrombopag NCT04797000 |
P2 | Active, not recruiting | Myelodysplastic Syndromes | 36 | 2025-04-26 (+33 mo) |
| NEPTUNUS-2 NCT05349214 |
P3 | Active, not recruiting | Sjogren Syndrome | 506 | 2025-05-13 (-10 mo) |
| ASC4START NCT05456191 |
P3 | Active, not recruiting | Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | 568 | 2025-05-15 (-21 mo) |
| VAYHIT2 NCT05653219 |
P3 | Active, not recruiting | Primary Immune Thrombocytopenia | 152 | 2025-06-19 |
| ASC2ESCALATE NCT05384587 |
P2 | Active, not recruiting | Chronic Myelogenous Leukemia - Chronic Phase | 34 | 2025-08-13 (+5 mo) |
| Remibrutinib NCT06042478 |
P3 | Active, not recruiting | Chronic Spontaneous Urticaria | 470 | 2025-09-17 (+1 mo) |
| MASter-1 NCT04641442 |
P2 | Active, not recruiting | NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations | 17 | 2025-10-14 (+21 mo) |
| FILIOS NCT06869785 |
P3 | Active, not recruiting | Relapsing Multiple Sclerosis (RMS) | 196 | 2026-01-28 (-11 mo) |
| VAY736 1ml PFS NCT06293365 |
P2 | Active, not recruiting | Sjögrens Disease; Systemic Lupus Erythematosus | 155 | 2026-02-17 (+5 mo) |
| VAYHIA NCT05648968 |
P3 | Active, not recruiting | Warm Autoimmune Hemolytic Anemia (wAIHA) | 90 | 2026-02-20 |
| NEOS NCT04926818 |
P3 | Active, not recruiting | Multiple Sclerosis (MS) | 129 | 2026-03-25 (-6 mo) |
| Remibrutinib NCT05976243 |
P3 | Active, not recruiting | Chronic Inducible Urticaria | 362 | 2026-05-11 (-2 mo) |
| PLATINUM NCT05750628 |
P2 | Recruiting | Uncomplicated Plasmodium Falciparum Malaria | 327 | 2026-06-09 (+11 mo) |
| ASTRALS NCT06643481 |
P2 | Active, not recruiting | Amyotrophic Lateral Sclerosis (ALS) | 251 | 2026-06-23 (-7 mo) |
| Remibrutinib NCT05147220 |
P3 | Active, not recruiting | Relapsing Multiple Sclerosis | 1000 | 2026-07-21 (+9 mo) |
| REMODEL-2 NCT05156281 |
P3 | Active, not recruiting | Relapsing Multiple Sclerosis | 1007 | 2026-07-22 (+9 mo) |
| Saline NCT06857955 |
P2 | Active, not recruiting | Hypertension | 396 | 2026-09-17 (-3 mo) |
| V-PLAQUE NCT05360446 |
P3 | Active, not recruiting | Coronary Artery Disease | 610 | 2026-10-26 (+17 mo) |
| VAYHIT1 NCT05653349 |
P3 | Active, not recruiting | Primary Immune Thrombocytopenia (ITP) | 226 | 2026-10-29 (+13 mo) |
| LOU064 (blinded) NCT05677451 |
P3 | Active, not recruiting | Chronic Spontaneous Urticaria | 100 | 2026-11-03 (+14 mo) |
| AAA617 NCT06004661 |
P2 | Active, not recruiting | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 23 | 2026-11-06 (+8 mo) |
| PSMAndARPI NCT06894511 |
P2 | Active, not recruiting | Metastatic Castration Resistant Prostate Cancer (mCRPC) | 7 | 2026-11-17 (-4 mo) |
| JSB462 NCT06991556 |
P2 | Active, not recruiting | Metastatic Hormone-sensitive Prostate Cancer | 168 | 2026-12-03 (-64 mo) |
| PSMACare NCT05849298 |
P2 | Active, not recruiting | Prostatic Neoplasm | 49 | 2026-12-23 (-23 mo) |
| Iptacopan NCT06388941 |
P2 | Active, not recruiting | Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | 84 | 2026-12-30 (-8 mo) |
| KontRASt-01 NCT04699188 |
P1/2 | Active, not recruiting | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung | 344 | 2027-01-25 (+35 mo) |
| EPIK-B5 NCT05038735 |
P3 | Active, not recruiting | Breast Cancer | 210 | 2027-01-28 (+3 mo) |
| APPEAR-C3G NCT04817618 |
P3 | Recruiting | C3G | 98 | 2027-01-29 (+42 mo) |
| Alpelisib NCT04544189 |
P2 | Active, not recruiting | Breast Neoplasms | 69 | 2027-01-29 (+39 mo) |
| LEE011 NCT02934568 |
P2 | Active, not recruiting | Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | 22 | 2027-02-01 (+58 mo) |
| LXH254 NCT04417621 |
P2 | Active, not recruiting | Melanoma | 134 | 2027-02-02 (+45 mo) |
| PLATINUM NCT07811908 |
P2 | Recruiting | Uncomplicated Plasmodium Falciparum Malaria | 120 | 2027-02-04 |
| ACS NCT07102628 |
P3 | Recruiting | Acute Coronary Syndrome | 300 | 2027-02-11 |
| RECLAIM NCT06868212 |
P3 | Active, not recruiting | Chronic Spontaneous Urticaria (CSU) | 409 | 2027-02-22 |
| Alpelisib NCT04524000 |
P2 | Active, not recruiting | Advanced Breast Cancer | 24 | 2027-02-26 (+44 mo) |
| everolimus NCT02962414 |
P3 | Active, not recruiting | Tuberous Sclerosis Complex | 206 | 2027-02-26 |
| EPIK-B2 NCT04208178 |
P3 | Active, not recruiting | Advanced HER2+Breast Cancer | 19 | 2027-02-26 (+35 mo) |
| LEE011 NCT01872260 |
P1/2 | Active, not recruiting | Breast Cancer | 259 | 2027-02-26 |
| CRYPTONITE NCT07249463 |
P2 | Recruiting | Cryptosporidiosis | 80 | 2027-03-23 |
| SIRIUS-SLE 1 NCT05639114 |
P3 | Active, not recruiting | Systemic Lupus Erythematosus | 436 | 2027-03-26 (+2 mo) |
| CTL019 NCT04094311 |
P3 | Recruiting | B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma | 200 | 2027-03-31 (+60 mo) |
| SIRIUS-SLE 2 NCT05624749 |
P3 | Active, not recruiting | Systemic Lupus Erythematosus | 288 | 2027-04-12 (+2 mo) |
| NeoB-Cap1 NCT06247995 |
P1/2 | Active, not recruiting | Breast Cancer | 20 | 2027-04-14 (-53 mo) |
| MAS825 NCT07203001 |
P2 | Recruiting | Still´s Disease | 30 | 2027-04-22 (-24 mo) |
| DII235 NCT07235046 |
P2 | Active, not recruiting | Lipoprotein Disorder | 234 | 2027-04-26 |
| QCZ484 NCT07610278 |
P2 | Recruiting | Hypercholesterolaemia | 120 | 2027-04-28 |
| Iptacopan NCT06517758 |
P3 | Active, not recruiting | Generalized Myasthenia Gravis | 146 | 2027-04-30 (+4 mo) |
| VICTORION-2P NCT05030428 |
P3 | Active, not recruiting | Atherosclerotic Cardiovascular Disease | 17004 | 2027-05-10 (+4 mo) |
| Remibrutinib Dose A NCT06799000 |
P3 | Active, not recruiting | Hidradenitis Suppurativa | 588 | 2027-05-17 (-16 mo) |
| GIA632 NCT07220577 |
P2 | Active, not recruiting | Atopic Dermatitis | 34 | 2027-05-17 |
| ARV-766 NCT05067140 |
P1/2 | Active, not recruiting | Prostate Cancer Metastatic | 164 | 2027-05-25 (+30 mo) |
| RECHARGE-2 NCT06840392 |
P3 | Active, not recruiting | Hidradenitis Suppurativa | 565 | 2027-06-03 (-12 mo) |
| EPIK-P3 NCT04980833 |
P2 | Active, not recruiting | PIK3CA-related Overgrowth Spectrum (PROS) | 41 | 2027-06-22 (-4 mo) |
| Rapcabtagene autoleucel single agent NCT03960840 |
P1/2 | Active, not recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 218 | 2027-06-30 (+55 mo) |
| JSB462 NCT07047118 |
P2 | Active, not recruiting | Prostatic Cancer, Castration-Resistant | 138 | 2027-07-16 (-7 mo) |
| LXE408 NCT06632600 |
P2 | Recruiting | Chagas Disease | 130 | 2027-07-22 |
| EYU688 NCT06006559 |
P2 | Recruiting | Dengue | 108 | 2027-07-22 (+33 mo) |
| STAR-1 NCT07467993 |
P2 | Recruiting | Schizophrenia | 142 | 2027-07-29 |
| Glycopyrronium bromide 25ug NCT05222529 |
P2 | Recruiting | Asthma | 42 | 2027-07-30 (+42 mo) |
| Capmatinib NCT03040973 |
P2 | Active, not recruiting | Advanced Solid Tumors Which Are cMET-dependent | 29 | 2027-07-30 (+100 mo) |
| Ianalumab NCT06470048 |
P2 | Active, not recruiting | Diffuse Cutaneous Systemic Sclerosis | 203 | 2027-07-30 (-11 mo) |
| BION-1301 NCT05852938 |
P3 | Active, not recruiting | IgA Nephropathy; Immunoglobulin A Nephropathy | 383 | 2027-08-10 (+13 mo) |
| YMI024 NCT07830719 |
P2 | Recruiting | Coronary Artery Disease | 180 | 2027-08-15 |
| Remibrutinib NCT06865651 |
P2 | Recruiting | Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) | 44 | 2027-08-23 (+2 mo) |
| Asciminib Pediatric formulation group NCT04925479 |
P1/2 | Active, not recruiting | Myeloid Leukemia, Philadelphia Positive | 46 | 2027-09-03 (+23 mo) |
| PKN605 NCT07217067 |
P2 | Recruiting | Atrial Fibrillation | 165 | 2027-09-09 |
| SIRIUS-LN NCT05126277 |
P3 | Active, not recruiting | Lupus Nephritis | 452 | 2027-09-21 (+29 mo) |
| DYP688 NCT05415072 |
P1/2 | Active, not recruiting | Metastatic Uveal Melanoma | 66 | 2027-10-01 (+23 mo) |
| Iptacopan NCT04747613 |
P3 | Active, not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 208 | 2027-10-18 (+17 mo) |
| CASSIOPEIA NCT03876769 |
P2 | Active, not recruiting | B-Cell Acute Lymphoblastic Leukemia | 121 | 2027-10-19 (+11 mo) |
| Iptacopan NCT06797518 |
P2 | Recruiting | Glomerulonephritis, IGA; Immunoglobulin A Nephropathy | 20 | 2027-11-27 |
| LOU064 NCT07681271 |
P2 | Recruiting | Papulopustular Rosacea | 100 | 2027-12-07 |
| LuMIERE NCT04939610 |
P1/2 | Recruiting | Solid Tumor | 222 | 2027-12-31 (+42 mo) |
| QMF149 NCT05562466 |
P3 | Recruiting | Asthma | 200 | 2028-02-01 (+25 mo) |
| ADD-VANTAGE NCT06813911 |
P3 | Active, not recruiting | Atherosclerotic Cardiovascular Disease (ASCVD) | 246 | 2028-02-03 (+5 mo) |
| rapcabtagene autoleucel NCT06581198 |
P2 | Active, not recruiting | Lupus Erythematosus, Systemic; Lupus Nephritis | 179 | 2028-02-14 (-16 mo) |
| decitabine NCT05201066 |
P2 | Active, not recruiting | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic | 33 | 2028-02-14 (+2 mo) |
| RELIEVE NCT06744920 |
P3 | Active, not recruiting | Generalized Myasthenia Gravis | 180 | 2028-02-25 |
| [177Lu]Lu-DOTA-TATE NCT05142696 |
P1/2 | Active, not recruiting | Extensive Stage Small Cell Lung Cancer | 55 | 2028-03-07 (+45 mo) |
| ORION-19 NCT06597006 |
P3 | Recruiting | Familial Hypercholesterolemia - Homozygous | 9 | 2028-03-21 |
| ORION-20 NCT06597019 |
P3 | Recruiting | Familial Hypercholesterolemia - Heterozygous | 60 | 2028-03-21 |
| ALIGN NCT04573478 |
P3 | Active, not recruiting | IgA Nephropathy; Immunoglobulin A Nephropathy | 404 | 2028-04-14 (+52 mo) |
| PSMA-DC NCT05939414 |
P3 | Recruiting | Oligometastatic Prostate Cancer (OMPC) | 450 | 2028-04-25 (+23 mo) |
| ITU512 NCT06546670 |
P1/2 | Recruiting | Sickle Cell Disease | 161 | 2028-05-01 (+6 mo) |
| REPLENISH-EXT NCT06331312 |
P3 | Active, not recruiting | Polymyalgia Rheumatica | 162 | 2028-05-08 (+2 mo) |
| MANIFEST-3 NCT07357727 |
P3 | Recruiting | Primary Myelofibrosis (PMF); Post-polycythemia Vera Myelofibrosis (PPV-MF) | 460 | 2028-05-17 |
| Remibrutinib NCT07816328 |
P3 | Recruiting | Chronic Spontaneous Urticaria | 382 | 2028-05-24 |
| EPIK-L1 NCT05948943 |
P2/3 | Recruiting | Lymphatic Malformations | 232 | 2028-05-31 (-18 mo) |
| VITESS NCT07431177 |
P2 | Recruiting | Non-segmental Vitiligo | 210 | 2028-06-06 |
| PSMAcTION NCT06780670 |
P2/3 | Recruiting | Prostate Cancer | 443 | 2028-06-27 (+2 mo) |
| AMO959 NCT07226986 |
P1/2 | Recruiting | PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | 123 | 2028-07-10 |
| Iptacopan NCT05935215 |
P3 | Recruiting | Atypical Hemolytic Uremic Syndrome | 50 | 2028-07-21 (-2 mo) |
| LEDA NCT05888493 |
P3 | Active, not recruiting | Follicular Lymphoma (FL) | 109 | 2028-07-25 (+2 mo) |
| VHB937 NCT07094516 |
P2 | Active, not recruiting | Alzheimer's Disease | 96 | 2028-09-14 |
| LUMINA IgAN NCT07850752 |
P3 | Not yet recruiting | IgA Nephropathy (IgAN) | 340 | 2028-09-17 |
| ECI830 NCT06726148 |
P1/2 | Recruiting | Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors | 280 | 2028-09-25 |
| AcTFirst NCT06855277 |
P3 | Recruiting | Prostate Cancer | 940 | 2028-09-29 (+9 mo) |
| ALITHIOS NCT03650114 |
P3 | Active, not recruiting | Relapsing Multiple Sclerosis | 1882 | 2028-09-30 (+40 mo) |
| APPARENT NCT05755386 |
P3 | Recruiting | IC-MPGN | 106 | 2028-10-27 (+34 mo) |
| Rapcabtagene autoleucel NCT07048197 |
P1/2 | Active, not recruiting | Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD) | 27 | 2028-11-01 (+5 mo) |
| ELIPSI NCT07775924 |
P2 | Recruiting | Cutaneous Lichen Planus | 259 | 2028-11-22 |
| GHZ339 NCT06947993 |
P2 | Recruiting | Atopic Dermatitis | 224 | 2028-11-27 |
| LTP NCT06649110 |
P1/2 | Recruiting | Healthy Volunteers, Pulmonary Arterial Hypertension | 232 | 2028-11-29 (+28 mo) |
| rapcabtagene autoleucel NCT06655896 |
P2 | Active, not recruiting | Scleroderma, Diffuse | 96 | 2028-11-30 |
| NETTER-3 NCT06784752 |
P3 | Recruiting | Somatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) | 240 | 2028-12-08 (+6 mo) |
| DDY391 NCT07801495 |
P2 | Recruiting | Moderate to Severe Psoriatic Arthritis | 220 | 2028-12-13 |
| Arumakimig NCT07748624 |
P2 | Recruiting | VEXAS Syndrome | 120 | 2028-12-26 |
| QVM149 NCT05776927 |
P3 | Recruiting | Asthma | 188 | 2028-12-30 (+33 mo) |
| VAY2EXPLORE NCT07421167 |
P2 | Recruiting | Primary Immune Thrombocytopenia (ITP); Primary Evans Syndrome (ES) | 164 | 2029-01-18 |
| Alpelisib NCT06997588 |
P2 | Recruiting | PIK3CA-related Overgrowth Spectrum (PROS) | 140 | 2029-01-29 (+6 mo) |
| ASC4TARGET NCT06514534 |
P2 | Recruiting | Chronic Myeloid Leukemia (CML) | 20 | 2029-02-17 (+3 mo) |
| DDY391 NCT07737743 |
P2 | Recruiting | Sjögren's Disease | 344 | 2029-02-19 |
| Remibrutinib NCT07811869 |
P3 | Recruiting | Chronic Pruritus of Unknown Origin | 180 | 2029-02-26 |
| Rapcabtagene autoleucel NCT06665256 |
P2 | Active, not recruiting | Idiopathic Inflammatory Myopathies | 21 | 2029-03-09 |
| NIO752 NCT07868328 |
P2 | Not yet recruiting | Progressive Supranuclear Palsy; Corticobasal Degeneration | 48 | 2029-03-26 |
| Remibrutinib NCT07768371 |
P3 | Recruiting | IgE-Mediated Food Allergy; Peanut Allergy | 576 | 2029-03-30 |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL NCT05739383 |
P3 | Active, not recruiting | Primary Prevention of Atherosclerotic Cardiovascular Disease | 14012 | 2029-04-16 |
| Midostaurin NCT03591510 |
P2 | Active, not recruiting | FLT3-mutated Acute Myeloid Leukemia | 22 | 2029-05-18 (+85 mo) |
| Rapcabtagene autoleucel NCT06868290 |
P2 | Active, not recruiting | ANCA Associated Vasculitis (AAV) | 126 | 2029-06-07 |
| KontRASt-R NCT07468071 |
P1/2 | Active, not recruiting | Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer; Advanced Solid Tumors Harboring the KRAS G12C Mutation | 25 | 2029-06-11 |
| SPARKLE NCT06439082 |
P3 | Recruiting | Sickle Cell Disease | 354 | 2029-07-02 (+3 mo) |
| Votoplam NCT06254482 |
P2 | Active, not recruiting | Huntington Disease | 144 | 2029-07-16 (+25 mo) |
| NIO752 NCT07498426 |
P3 | Recruiting | Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) | 300 | 2029-07-20 |
| Remibrutinib oral treatment NCT06846281 |
P3 | Recruiting | Relapsing Multiple Sclerosis | 400 | 2029-07-25 (-7 mo) |
| THALASSA NCT07621809 |
P3 | Recruiting | Sjögren´s Disease | 570 | 2029-08-15 |
| FWY003 NCT07441642 |
P2 | Recruiting | Geographic Atrophy Secondary to Age-related Macular Degeneration | 272 | 2029-08-21 |
| Adjuvant WIDER NCT05827081 |
P3 | Active, not recruiting | Early Breast Cancer | 1466 | 2029-09-07 (-10 mo) |
| YTB323 NCT06704269 |
P1/2 | Active, not recruiting | Generalized Myasthenia Gravis | 15 | 2029-10-26 (+3 mo) |
| TulmiSTAR-01 NCT07206056 |
P1/2 | Recruiting | Progressive Metastatic Castrate Resistant Prostate Cancer | 188 | 2029-11-09 |
| DDY391 NCT07923773 |
P2 | Not yet recruiting | Moderate to Severe Psoriatic Arthritis | 88 | 2029-12-12 |
| Remibrutinib NCT07700056 |
P3 | Recruiting | Chronic Pruritus of Unknown Origin | 180 | 2029-12-19 |
| Pelabresib NCT06401356 |
P3 | Recruiting | Hematologic Malignancy; Solid Tumor | 50 | 2029-12-31 (+66 mo) |
| Pelacarsen (TQJ230) NCT07517263 |
P3 | Active, not recruiting | Cardiovascular Disease and Lipoprotein(a) | 5700 | 2030-01-09 |
| Tulmimetostat NCT04104776 |
P1/2 | Recruiting | Advanced Solid Tumor; Diffuse Large B Cell Lymphoma | 300 | 2030-02-27 (+50 mo) |
| Pelacarsen (TQJ230) 80mg NCT05646381 |
P2 | Recruiting | Aortic Stenosis | 502 | 2030-03-12 (+26 mo) |
| INVEST-HD NCT07326709 |
P3 | Recruiting | Huntington Disease | 770 | 2030-04-02 |
| NATALEE NCT03701334 |
P3 | Active, not recruiting | Early Breast Cancer | 5101 | 2030-05-29 (+54 mo) |
| rapcabtagene autoleucel (YTB323) NCT06675864 |
P1/2 | Active, not recruiting | Progressive Multiple Sclerosis | 28 | 2030-06-14 |
| iptacopan NCT06994845 |
P3 | Recruiting | Primary Immunoglobulin A Nephropathy (IgAN) | 31 | 2030-06-28 |
| SHIFT NCT07146906 |
P2 | Recruiting | Immunoglobulin A Nephropathy (IgAN) | 32 | 2030-07-12 (+3 mo) |
| rapcabtagene autoleucel (YTB323) NCT06617793 |
P1/2 | Active, not recruiting | Relapsing Multiple Sclerosis | 28 | 2030-08-07 |
| REMASTER NCT07225504 |
P3 | Recruiting | Secondary Progressive Multiple Sclerosis (SPMS) | 1275 | 2030-12-03 |
| LNP023 NCT04557462 |
P3 | Recruiting | Primary IgA Nephropathy | 540 | 2030-12-04 (+30 mo) |
| Pelacarsen (TQJ230) NCT06875973 |
P3 | Active, not recruiting | Atherosclerotic Cardiovascular Disease | 599 | 2030-12-08 (+35 mo) |
| LILAC-TIMI 76 NCT07739888 |
P3 | Not yet recruiting | Atrial Fibrillation (AF) | 2500 | 2030-12-30 |
| DJI136 NCT07564401 |
P1/2 | Recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 80 | 2031-03-03 |
| SPECTRUM NCT05335876 |
P3 | Active, not recruiting | Spinal Muscular Atrophy (SMA) | 20 | 2031-04-29 (-102 mo) |
| GVV858 NCT07288359 |
P1/2 | Recruiting | Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors | 205 | 2031-05-09 |
| CYStem NCT06910813 |
P1/2 | Recruiting | Nephropathic Cystinosis | 30 | 2031-05-28 (+9 mo) |
| QCZ484 NCT07543120 |
P2 | Recruiting | Hypertension (HTN) | 323 | 2031-05-31 |
| zigakibart NCT06858319 |
P3 | Recruiting | Kidney Diseases; Kidney Diseases, Chronic | 220 | 2031-06-25 |
| ADVANCE NCT07498335 |
P3 | Recruiting | Berger Disease; Bergers Disease | 28 | 2031-09-15 |
| LNP023 NCT06934967 |
P3 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 12 | 2031-10-14 |
| Remibrutinib NCT07665437 |
P3 | Recruiting | Hidradenitis Suppurativa | 710 | 2031-10-15 |
| EPIK-RO NCT07679269 |
P2 | Not yet recruiting | PIK3CA-Related Overgrowth Spectrum (PROS); Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) | 51 | 2032-03-23 |
| V-PEDS-OLE NCT05682378 |
P3 | Recruiting | Heterozygous or Homozygous Familial Hypercholesterolemia | 195 | 2032-03-25 (+52 mo) |
| Iptcaopan 200 mg NCT05795140 |
P3 | Recruiting | Atypical Hemolytic Uremic Syndrome | 65 | 2032-07-16 (+58 mo) |
| TulmiSTAR-02 NCT07190300 |
P1/2 | Recruiting | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 181 | 2032-08-02 (+3 mo) |
| Remibrutinib NCT07456891 |
P3 | Recruiting | Indication of the Parent Protocol | 650 | 2033-01-30 |
| Asciminib single agent NCT07354074 |
P2 | Recruiting | Chronic Myelogenous Leukemia; Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | 50 | 2033-02-23 |
| NEPTUNUS-Ext NCT05985915 |
P3 | Active, not recruiting | Sjogrens Syndrome | 612 | 2033-04-22 (+56 mo) |
| VAYHIT-P NCT07660172 |
P2 | Not yet recruiting | Primary Immune Thrombocytopenia (ITP) | 36 | 2033-04-22 |
| Asciminib Adult formulation NCT07387926 |
P1/2 | Recruiting | Acute Lymphoblastic Leukemia; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | 50 | 2033-09-19 |
| SIRIUS-SLE LTE NCT06133972 |
P3 | Recruiting | Systemic Lupus Erythematosus | 550 | 2034-04-03 (+28 mo) |
| SIRIUS-LN ext NCT06711887 |
P3 | Recruiting | Lupus Nephritis | 348 | 2035-08-01 (+61 mo) |
| LNP023 NCT03955445 |
P3 | Recruiting | C3 Glomerulopathy; Immune-complex-membranoproliferative Glomerulonephritis | 225 | 2036-05-30 |
| PAVO NCT02445222 |
P3 | Recruiting | Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | 1105 | 2039-04-18 (+39 mo) |